デフォルト表紙
市場調査レポート
商品コード
1001796

がんペプチドワクチンの世界市場 - 臨床試験の考察:2026年

Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026

出版日: | 発行: KuicK Research | ページ情報: 英文 275 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.50円

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

がんペプチドワクチンの世界市場 - 臨床試験の考察:2026年
出版日: 2021年04月22日
発行: KuicK Research
ページ情報: 英文 275 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ワクチンの開発は、人間の健康システムに信じられないほどの影響を示し、いくつかの病気による死亡率の大幅な低下をもたらしました。がんを含む慢性疾患の有病率の増加が、新興の標的治療の開発を促しています。最近では、研究者はがんの投与において、抗腫瘍反応を生み出すワクチンの使用を利用しています。

当レポートでは、世界のがんペプチドワクチン市場について調査分析し、市場動向、市場機会、臨床試験の考察などについて、体系的な情報を提供しています。

目次

第1章 がんペプチドワクチンのイントロダクション

第2章 ペプチドワクチンの必要性

  • ペプチドの理由 - 望ましい
  • ペプチドワクチン vs. 従来型ワクチン

第3章 ペプチドワクチンの分類

  • 摂取源別
  • 長さ別
  • エピトープ別

第4章 がんペプチドワクチンの作用機序

  • がんペプチドワクチンによって活性化された免疫細胞
  • 合成ペプチドワクチンの開発手順

第5章 急性骨髄性白血病に対するWT1腫瘍性タンパク質から摂取した合成ペプチド類似体の臨床試験有効性の分析

  • 研究の基本的なレイアウト
  • WT1ペプチドのイントロダクション
  • 臨床研究に含まれる手法
  • 臨床試験の結果

第6章 主要ながんに対するがんペプチドワクチンの広範囲な作用

  • 大腸がん
  • 肺がん
  • 膵臓がん
  • 胃がん
  • 前立腺がん
  • 乳がん

第7章 世界のがんペプチドワクチン市場の概要

第8章 世界のがんペプチドワクチン市場の動向

  • 最適化された不可解なペプチド
  • がん治療用CpGペプチドベースのワクチン
  • 合成長ペプチドによる個別化された新抗原ワクチン
  • 組換えペプチドワクチン
  • p53ペプチドのパルスされた樹状細胞ワクチン

第9章 世界のがんペプチドワクチンのパイプラインの概要

  • 国別
  • 企業別
  • 患者セグメント別
  • フェーズ別

第10章 世界のがんペプチドワクチンの臨床試験の考察

  • 研究
  • 前臨床
  • フェーズI
  • フェーズI/II
  • フェーズII
  • フェーズIII

第11章 LucaVax - 最初に上市されたがんペプチドワクチン

第12章 世界のがんペプチドワクチン市場力学

  • 市場促進要因
  • がんペプチドワクチン市場の発展に対する今後の課題

第13章 がんペプチドワクチン:がん免疫療法の有力候補

第14章 競合情勢

  • Enzo Life Science (Alexis Biotech)
  • Antigen Express
  • BioLife Science
  • Immatics Biotechnologies
  • Immune Design
  • Imugene
  • Immunomedics
  • ISA Pharmaceuticals
  • Galena Biopharma
  • Generex Biotechnology Corporation
  • Lytix Biopharma
  • Merck (Merck Serono)
  • OncoTherapy Science
  • Oncothyreon
  • Pfizer
  • Phylogica
  • Symphogen (Receptor BioLogix)
  • Sumitomo Dainippon Pharma
  • TapImmune
  • Vaxon Biotech
図表

List of Figures

  • Figure 1-1: Advantages of Peptide Cancer Vaccines
  • Figure 2-1: Peptides - Amino Acid & Proteins
  • Figure 2-2: Diversification of Vaccines
  • Figure 2-3: Sub-Unit Vaccines V/S Traditional Vaccines
  • Figure 3-1: Classification of Peptide Vaccine by Source
  • Figure 3-2: Classification on Basis of Length
  • Figure 3-3: On the Basis of Epitopes
  • Figure 4-1: Immunological Cells Activated By Peptide Cancer Vaccines
  • Figure 4-2: Procedure of Synthetic Peptide Cancer Vaccine Development
  • Figure 4-3: Determination of Antigen Components, Its Selection & Construction
  • Figure 4-4: Role of Adjuvants in Peptide Cancer Vaccines
  • Figure 4-5: Investigation of Efficiency & Immune Response to Synthetic Peptide Cancer Vaccine
  • Figure 5-1: Clinical Trial Study of WT1 Peptide Vaccine for Acute Myeloid Leukemia Patients
  • Figure 5-2: WT1 Peptide as a Marker for Cancer Therapy
  • Figure 5-3: Methodologies Involved In the Clinical Study
  • Figure 6-1: Peptides & Colorectal Cancer
  • Figure 6-2: Peptides & Lung Cancer
  • Figure 6-3: Peptides & Pancreatic Cancer
  • Figure 6-4: Peptides & Gastric Cancer
  • Figure 6-5: Peptides & Prostate Cancer
  • Figure 6-6: Peptides & Breast Cancer
  • Figure 7-1: Global - Peptide Therapeutic Market Size (US$ Billion), 2018 - 2026
  • Figure 7-2: Global - Total Peptide Therapeutic Market Size vs. Oncological Peptide Therapeutic Market Size (US$ Billion), 20120
  • Figure 7-3: Global - Oncological Peptide Therapeutics Market Share in Total Peptide market (%), 2020
  • Figure 7-4: Global - Peptide Oncology Drugs Market Size (US$ Billion), 2018 - 2026
  • Figure 7-5: Peptide Oncology Market - Regional Market Share (%), 2019
  • Figure 8-1: Optimized Cryptic Peptides
  • Figure 8-2: Therapeutic CpG Peptide-Based Cancer Vaccine
  • Figure 8-3: Personalized Neoantigen Vaccination with Synthetic Long Peptides
  • Figure 8-4: Recombinant Peptide Vaccine
  • Figure 8-5: p53 Peptide-Pulsed Dendritic Cells Cancer Vaccine
  • Figure 9-1: Global - Peptide Cancer Vaccine in Clinical Pipeline by Country, 2021 till 2026
  • Figure 9-2: Global - Peptide Cancer Vaccine in Clinical Pipeline by Company, 2021 till 2026
  • Figure 9-3: Global - Peptide Cancer Vaccine in Clinical Pipeline by Patient Segment, 2021 till 2026
  • Figure 9-4: Global - Peptide Cancer Vaccine in Clinical Pipeline by Phase, 2021 till 2026
  • Figure 12-1: Market Drivers of Peptide Cancer Vaccines
  • Figure 12-2: Peptide Cancer Vaccine: An Active Immunotherapy
  • Figure 12-3: Peptide Cancer Vaccine: A Personalized, Targeted Therapy
  • Figure 12-4: Peptide Cancer Vaccine: Highly Efficient, High Immunogenic Response Generating
  • Figure 12-5: Peptide Cancer Vaccine: Multiple Tumors Targeting Ability
  • Figure 12-6: Peptide Cancer Vaccine: A Viable Solution to Immunotolerance
  • Figure 12-7: Peptide Cancer Vaccine: Improves the Quality Of Life & is Cost Effective
  • Figure 12-8: Challenges of Peptide Cancer Vaccine: The Parameters Related To the Clinical Trials
  • Figure 12-9: Single Antigen Based Peptide Vaccine: Highly Prone To Failure
  • Figure 12-10: Lack of Standardized Parameters for Assessing the Result of Clinical Trials
  • Figure 12-11: Variable Therapeutic Window for Different Patients
  • Figure 12-12: Cancer Immunoediting: The Three Es; Tumor Elimination, Equilibrium & Escape
  • Figure 14-1: Enzo Life Science Pipeline
  • Figure 14-2: Immatics Biotechnologies Pipeline
  • Figure 14-3: Immune Design Pipeline
  • Figure 14-4: Imugene Pipeline
  • Figure 14-5: ISA Pharmaceuticals Pipeline
  • Figure 14-6: Galena Biopharma Pipeline
  • Figure 14-7: Generex Biotechnology Pipeline
  • Figure 14-8: Lytix Biopharma Pipeline
  • Figure 14-9: Merck Clinical Pipeline
  • Figure 14-10: Onco Therapy Science Pipeline
  • Figure 14-11: Oncothyreon Pipeline
  • Figure 14-12: Sumitomo Dainippon Pharma Pipeline
  • Figure 14-13: Tapimmune Pipeline
  • Figure 14-14: Vaxon Biotech Pipeline
目次

“Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026” Report Highlights:

  • Global Peptide Cancer Vaccine Market Trends Insight
  • Global Peptide Cancer Drugs Market Opportunity: >USD 20 Billion
  • Global Peptide Cancer Vaccine Clinical Trials Insight By Company, Indication & Phase
  • Number Of Peptide Vaccines In Pipeline: >90
  • Application of Peptide Cancer Vaccine Against Major Cancer

The developments of vaccines have shown incredible impact on human health system and have resulted in significant decrease in mortality rates from several diseases. Increase in prevalence of chronic disorders including cancer has urged the development of novel targeted therapeutics for their management. In recent times, researchers have exploited the use of vaccines to generate anti-tumor response in management of cancer.

The rapid approval of Provenge for the management of pancreatic cancer and the robust response in market has surged the development of more targeted vaccines in cancer. In recent times, peptides have emerged as a potential vaccine candidate owing to their small size, simple and cost efficient production and development process. Moreover, peptides are recognized to be highly specific and efficacious, safe and well tolerated. Given their attractive physical and chemical properties, researchers have developed several peptide based vaccines in management of wide range of cancers.

Currently, GV1001 (Riavaxtm, Tertomotide) is the only peptide based vaccine approved for the management of pancreatic cancer in Korea. , GV1001 is a 16-amino-acid peptide comprising a sequence from the human enzyme telomerase reverse transcriptase (TERT). Most cancers highly express TERT, and immunization with GV1001 aims to activate the immune system to recognize and kill cancer cells. The vaccine is currently under clinical trials and applications to gain approval in other countries.

Apart from this, a cocktail of peptide based cancer vaccines are present in preclinical and clinical studies and have shown encouraging response. Most of the drugs are present in the phase I and II clinical trials which suggests that the market will be flourished with several vaccines targeting different cancers in next 4-5 years. Moreover, in near future the market will see combination of vaccines along with other conventional drugs to improve their efficacy and specificity in targeting the complexity of cancer cells.

Keeping in mind the high adoption rates of the novel therapeutics in North America, it is expected that the region will dominate the global peptide cancer vaccine market for next few years. The high prevalence of cancer and the rising initiatives by government as well as private sectors will also propel the growth of peptide cancer vaccines in this area. In addition to this, Europe and Asia Pacific will also emerge as a potential market wing to high untapped opportunities, low cost of raw material, growing base of companies providing outsourcing services, flourishing biotech industry, and increasing investments in the R&D sector.

As per “Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026” report findings, it is estimated that the global peptide cancer vaccine will follow trajectory growth rates. The market will be favored by the advancement in science and arrival of novel technologies which will further enable the identification of potential targets in developing cancer vaccines. The arrival of peptide based cancer vaccine has caused prompting effects on the overall cancer therapy market and has helped it to make through all the challenges that have been on the way of becoming the most dominant market in the industry.

Table of Contents

1. Introduction to Peptide Cancer Vaccine

2. Need of Peptide Vaccines

  • 2.1 Why Peptides - More Desirable
  • 2.2 Peptide Vaccines V/S Traditional Vaccines

3. Classification of Peptide Vaccines

  • 3.1 On the Basis of Sources Obtained
  • 3.2 On the Basis of Length
  • 3.3 On the Basis of Epitopes

4. Mechanism of Action of Peptide Cancer Vaccines

  • 4.1 Immunological Cells Activated by Peptide Cancer Vaccines
  • 4.2 Procedure of Synthetic Peptide Vaccine Development

5. Clinical Trials Efficacy Study of Synthetic Peptide Analog Obtained From WT1 Oncoprotein against Acute Myeloid Leukemia

  • 5.1 Basic Layout of the Study
  • 5.2 Introduction to WT1 Peptide
  • 5.3 Methodologies Involved In the Clinical Study
  • 5.4 Results of the Clinical Trial Study

6. Wide Spectrum Action of Peptide Cancer Vaccines Against Major Cancer

  • 6.1 Colorectal Cancer
  • 6.2 Lung Cancer
  • 6.3 Pancreatic Cancer
  • 6.4 Gastric Cancer
  • 6.5 Prostate Cancer
  • 6.6 Breast Cancer

7. Global Peptide Cancer Vaccine Market Overview

8. Global Peptide Cancer Vaccine Market Trends

  • 8.1 Optimized Cryptic Peptides
  • 8.2 Therapeutic CpG Peptide-Based Cancer Vaccine
  • 8.3 Personalized Neoantigen Vaccination with Synthetic Long Peptides
  • 8.4 Recombinant Peptide Vaccine
  • 8.5 p53 Peptide-Pulsed Dendritic Cells Cancer Vaccines

9. Global Peptide Cancer Vaccine Pipeline Overview

  • 9.1 By Country
  • 9.2 By Company
  • 9.3 By Patient Segment
  • 9.4 By Phase

10. Global Peptide Cancer Vaccine Clinical Trials Insight

  • 10.1 Research
  • 10.2 Preclinical
  • 10.3 Phase-I
  • 10.4 Phase-I/II
  • 10.5 Phase-II
  • 10.6 Phase-III

11. LucaVax - First Commercially available Peptide Cancer Vaccine

12. Global Peptide Cancer Vaccine Market Dynamics

  • 12.1 Market Driving Factors
  • 12.2 Challenges Ahead For Peptide Cancer Vaccine Market Development

13. Peptide Cancer Vaccine: Promising Candidate of Cancer Immunotherapy

14. Competitive Landscape

  • 14.1 Enzo Life Science (Alexis Biotech)
  • 14.2 Antigen Express
  • 14.3 BioLife Science
  • 14.4 Immatics Biotechnologies
  • 14.5 Immune Design
  • 14.6 Imugene
  • 14.7 Immunomedics
  • 14.8 ISA Pharmaceuticals
  • 14.9 Galena Biopharma
  • 14.10 Generex Biotechnology Corporation
  • 14.11 Lytix Biopharma
  • 14.12 Merck (Merck Serono)
  • 14.13 OncoTherapy Science
  • 14.14 Oncothyreon
  • 14.15 Pfizer
  • 14.16 Phylogica
  • 14.17 Symphogen (Receptor BioLogix)
  • 14.18 Sumitomo Dainippon Pharma
  • 14.19 TapImmune
  • 14.20 Vaxon Biotech